Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Matrikine Peptides
Overview
Matrikine peptides are bioactive fragments released from extracellular matrix proteins during tissue remodeling or injury. These sequences, derived from collagen, elastin, fibronectin, and laminin, regulate cellular processes including migration, proliferation, and differentiation by binding to cell surface receptors.
Mechanism of Action
Matrikines serve as endogenous signals coordinating wound healing and tissue homeostasis.
Research Summary & Key Findings
Preclinical research has identified multiple matrikine sequences with distinct activities, such as the elastin-derived VGVAPG hexapeptide promoting chemotaxis and the collagen-derived DGEA sequence supporting cell adhesion. In vitro and animal models have demonstrated roles in angiogenesis, inflammation resolution, and matrix synthesis. Clinical translation has been limited to topical cosmetic applications, with no approved pharmaceutical indications.
Clinical Status
Matrikine Peptides is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Matrikine Peptides"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Matrikine Peptides"
Registered interventional and observational studies, including status and phase.
- PubChem: "Matrikine Peptides"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsNo lawful pathway today
Matrikine Peptides is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.